Clinical Trials
2 trialsNCT04539808 2026-01-14
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT01821729 2020-09-25
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown